[go: up one dir, main page]

MX2013008197A - Sales de aminas organicas de azilsartan, metodo de preparacion y uso de las mismas. - Google Patents

Sales de aminas organicas de azilsartan, metodo de preparacion y uso de las mismas.

Info

Publication number
MX2013008197A
MX2013008197A MX2013008197A MX2013008197A MX2013008197A MX 2013008197 A MX2013008197 A MX 2013008197A MX 2013008197 A MX2013008197 A MX 2013008197A MX 2013008197 A MX2013008197 A MX 2013008197A MX 2013008197 A MX2013008197 A MX 2013008197A
Authority
MX
Mexico
Prior art keywords
azilsartan
preparation
organic amine
amine salts
disclosed
Prior art date
Application number
MX2013008197A
Other languages
English (en)
Other versions
MX340590B (es
Inventor
Baohai Yang
Bigao Pan
Longbin Huang
Original Assignee
Jiangsu Hanson Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hanson Pharmaceutical Co Ltd filed Critical Jiangsu Hanson Pharmaceutical Co Ltd
Publication of MX2013008197A publication Critical patent/MX2013008197A/es
Publication of MX340590B publication Critical patent/MX340590B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se dan a conocer sales de aminas orgánicas de azilsartán, un método de preparación y uso del mismo. En particular, se dan a conocer sales de aminas orgánicas de azilsartán, su método de preparación, la composición farmacéutica que comprende compuesto en una cantidad terapéuticamente efectiva, y su uso para la fabricación de medicamentos antihipertensivos.
MX2013008197A 2011-01-20 2012-01-11 Sales de aminas organicas de azilsartan, metodo de preparacion y uso de las mismas. MX340590B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201110022311 2011-01-20
PCT/CN2012/070219 WO2012097697A1 (zh) 2011-01-20 2012-01-11 阿齐沙坦有机胺盐及其制备方法和用途

Publications (2)

Publication Number Publication Date
MX2013008197A true MX2013008197A (es) 2013-11-22
MX340590B MX340590B (es) 2016-07-13

Family

ID=46515148

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008197A MX340590B (es) 2011-01-20 2012-01-11 Sales de aminas organicas de azilsartan, metodo de preparacion y uso de las mismas.

Country Status (12)

Country Link
US (1) US9233954B2 (es)
EP (1) EP2666773B1 (es)
JP (1) JP5981940B2 (es)
CN (1) CN102603723B (es)
AU (1) AU2012208863B2 (es)
BR (1) BR112013017982A2 (es)
CA (1) CA2824316C (es)
MX (1) MX340590B (es)
RU (1) RU2600986C2 (es)
TW (1) TWI519531B (es)
WO (1) WO2012097697A1 (es)
ZA (1) ZA201305059B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103113364B (zh) * 2012-08-27 2015-11-18 南京华威医药科技开发有限公司 阿齐沙坦多晶型的制备方法
CN103601723B (zh) * 2013-11-19 2016-04-27 合肥远志医药科技开发有限公司 一种阿齐沙坦的工业化生产方法
JP2017036215A (ja) * 2013-12-27 2017-02-16 トーアエイヨー株式会社 アンジオテンシンii受容体拮抗物質の塩
CN105037341B (zh) * 2014-04-04 2019-12-03 江苏豪森药业集团有限公司 阿齐沙坦醇铵晶型及其制备方法
CN105503848A (zh) * 2014-10-13 2016-04-20 江苏豪森药业集团有限公司 阿齐沙坦有机胺盐复合物及其制备方法和用途
CZ2014702A3 (cs) 2014-10-15 2016-04-27 Zentiva, K.S. Způsob přípravy vysoce čistého azilsartanu
CN108113988A (zh) * 2016-11-29 2018-06-05 江苏恒瑞医药股份有限公司 一种romk抑制剂与arb联合在制备治疗和/或预防高血压或心力衰竭的药物中的用途
CN107286145A (zh) * 2017-08-14 2017-10-24 广州奈米微晶生物科技有限公司 一种阿齐沙坦哌嗪盐溶剂合物及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
ZA924666B (en) * 1991-06-27 1993-12-24 Takeda Chemical Industries Ltd Heterocyclic compounds, their production and use
CN1216873C (zh) * 2000-07-19 2005-08-31 诺瓦提斯公司 缬沙坦的盐
CA2468827A1 (en) * 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
JP4484427B2 (ja) * 2001-12-03 2010-06-16 武田薬品工業株式会社 インスリン抵抗性改善剤
US7157584B2 (en) 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
BRPI0516246A (pt) * 2004-10-07 2008-08-26 Takeda Pharmaceutical agente para a profilaxia ou tratamento de sìndrome metabólica, método para a profilaxia ou tratamento de sìndrome metabólica em um mamìfero, e, uso de ácido 2-etóxi-1-[ [2'-(5-oxo-2,5-diidro-1,2,4-oxadiazol-3-il) bifenil-4-il]metil] -1h-benzimidazol-7-carboxìlico ou um sal do mesmo ou uma pró-droga do mesmo em combinação com uma substáncia semelhante ao agonista de ppargama
SI22297A (sl) * 2006-06-23 2007-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava soli telmisartana
CZ2008469A3 (cs) * 2008-07-31 2009-10-29 Zentiva, A. S. Telmisartan tablety
WO2010075347A2 (en) 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
CN101921264A (zh) * 2009-06-15 2010-12-22 江苏豪森医药集团有限公司 坎地沙坦有机胺盐及其制备方法和用途
BR112012012484A2 (pt) * 2009-11-30 2016-04-12 Jiangsu Hansoh Pharmaceutical "sais de amina orgânicos de azilsartan, método de preparação e uso dos mesmos".

Also Published As

Publication number Publication date
US20130296334A1 (en) 2013-11-07
ZA201305059B (en) 2015-01-28
TW201309684A (zh) 2013-03-01
RU2013137223A (ru) 2015-02-27
CN102603723B (zh) 2014-10-08
BR112013017982A2 (pt) 2020-10-27
CN102603723A (zh) 2012-07-25
AU2012208863B2 (en) 2016-07-28
AU2012208863A1 (en) 2013-08-01
JP5981940B2 (ja) 2016-08-31
EP2666773B1 (en) 2017-07-26
RU2600986C2 (ru) 2016-10-27
EP2666773A8 (en) 2014-02-12
TWI519531B (zh) 2016-02-01
US9233954B2 (en) 2016-01-12
EP2666773A1 (en) 2013-11-27
JP2014502978A (ja) 2014-02-06
HK1169826A1 (en) 2013-02-08
CA2824316A1 (en) 2012-07-26
WO2012097697A1 (zh) 2012-07-26
EP2666773A4 (en) 2014-06-11
CA2824316C (en) 2020-07-07
MX340590B (es) 2016-07-13

Similar Documents

Publication Publication Date Title
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
MX340590B (es) Sales de aminas organicas de azilsartan, metodo de preparacion y uso de las mismas.
PH12016500072A1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
MA37400A1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
PH12014500987A1 (en) Neprilysin inhibitors
IN2015DN00185A (es)
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
WO2012117000A8 (en) 3-amino-pyridines as gpbar1 agonists
EP2657231A4 (en) SUBSTITUTED AZOLES, ANTIVIRAL ACTIVE INGREDIENT, PHARMACEUTICAL COMPOSITION AND PROCESS FOR PREPARING AND USING SAME
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
IL232035A (en) These heterocyclic compounds, these compounds as a medicine and a pharmaceutical composition containing them
WO2013004995A8 (en) Pyrimidinone compounds and their use
MX340233B (es) Agonistas de receptores de neurotrofina y sus usos como medicamentos.
SG194463A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
IL223872A (en) Pyrazoloquinoline derivatives and intermediates, process for preparation, use and pharmaceutical preparations and preparations containing them
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
MX2014003701A (es) Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio.
MX2013011926A (es) Derivados de glicosido y usos de los mismos.
ZA201309559B (en) Comptothecin derivative, method for preparing same, pharmaceutical composition and use thereof
TN2014000060A1 (en) Benzothiazolone compound
IN2014DN10669A (es)

Legal Events

Date Code Title Description
FG Grant or registration